Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
A phase 3 trial of Efbemalenograstim alfa in Breast cancer, run by EVIVE Biotechnology, completed.
Overview
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy is a phase 3 interventional study registered as NCT02872103 by EVIVE Biotechnology, with 122 participants recorded, started 2016-08 and reaching its primary completion in 2017-12-20. Interventions recorded: F-627, Placebo. Conditions recorded: Breast Cancer, Neutropenia.
Linked to the drug Efbemalenograstim alfa because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy to Compare the Efficacy and Safety of F-627 and GRAN®
Shares Evive Biotech, Efbemalenograstim alfa, Breast cancer (all types) and the tag pipeline.
- TrialNeulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Shares Evive Biotech, Efbemalenograstim alfa, Breast cancer (all types) and the tag pipeline.
- TrialImplementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
Shares Breast cancer (all types) and the tag pipeline.
- TrialCryoablation Versus Lumpectomy in Early-Stage Breast Cancer
Shares Breast cancer (all types) and the tag pipeline.
- TrialPrevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling
Shares Breast cancer (all types) and the tag pipeline.
- TrialComparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study)
Shares Breast cancer (all types) and the tag pipeline.
- TrialDiagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer
Shares Breast cancer (all types) and the tag pipeline.
- Trial[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
Shares Breast cancer (all types) and the tag pipeline.